Kidron Nadav's Form 4/A amendment
AmendedOramed Pharmaceuticals Inc. (ORMP) · filed Dec 7, 2021
- Accession no.
- 0001213900-21-063945
- Filed
- Dec 7, 2021
- Trade date
- Aug 9, 2021
- Filing delay
- 120 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Aug 11, 2021
This filing lists 1 non-derivative transaction. Open-market sales total $4.42M. It was filed 120 days after the trade.
This amendment replaces 0001213900-21-041711 (filed Aug 11, 2021).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kidron NadavCIK 0001351779 | Director, Officer (President and CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 9, 2021 | Common Stock | SSaleDisposed | −220,000 | $20.11F2 | −$4,424,200 | 738,209 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 18, 2021.
- F2
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 18, 2021.
Referenced by the price of 1 transaction in Table I.
- F3
This amendment is being filed to correct an administrative error in Form 4 filed by Mr. Kidron, which reported that 648,573 shares of common stock are beneficially owned by him following the reported transaction. Mr. Kidron beneficially owned 738,209 shares of common stock following the reported transaction.